Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

Non-Hodgkin’s lymphoma (NHL) is the seventh most common cancer in the United States, with approximately 56,200 new cases diagnosed each year.[1] Recent evidence shows that the mortality rate is increasing.[2] Although many patientand disease-related factors such as age, performance status, comorbidities, stage, histology, laboratory values (eg, lactate dehydrogenase [LDH] level), and treatment affect survival, clinicians can only alter treatment. Among NHL patients, those with intermediate-grade disease are considered potentially curable, based on data from randomized clinical trials.[3-5]